David J Straus MD

Hematologic Oncology

Professor of Clinical Medicine, Weill Cornell Medical College

525 East 72nd Street18GNew York, NY 10021
Phone+1 646-207-0455

Dr. Straus is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Straus' full profile Already have an account?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1975 - 1977
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1972 - 1973
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1969 - 1972
Medical College of WisconsinClass of 1969

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 1974 - Present
FL State Medical License 2022 - Present
NY State Medical License 1970 - 2027
NJ State Medical License Active through 2023
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2016-2017
CMS Meaningful Use Stage 1 Certification MyMSK, Memorial Sloan Kettering, 2016-2017
Top Cancer Docters Newsweek, 2015

Clinical Trials

Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED
PHASE3
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma
COMPLETED
PHASE2
St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer
COMPLETED
PHASE3

Publications & Presentations

PubMed

Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary.
Jeremy S Abramson, David J Straus, Nancy L Bartlett, John M Burke, Ryan C Lynch
Future Oncology. 2026-07-01
2 citations
Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma.
Jeremy S Abramson, David J Straus, Nancy L Bartlett, John M Burke, Ryan C Lynch
Blood. 2026-04-09
1 citations
Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.
Raphael Steiner, Liana Nikolaenko, Ranjit Nair, Venkatraman Seshan, Swetha Kambhampati Thiruvengadam
Blood Advances. 2025-11-11

Journal Articles

CALBG 50604: Risk-Adapted Treatment of Non-Bulky Early Stage Hodgkin Lymphoma Based on Interim PET
David J Straus, Heiko Schoder, John C Grecula, Eric D Hsi, Leslie L Popplewell, John P Leonard, Craig H Moskowitz, Brad S Kahl, Jonathan W Friedberg, Nancy L Bartlett, Blood

Abstracts/Posters

Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution
David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma
David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of ...
David J. Straus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: Three-year update of the ECHELON-1 study.
2019 ASCO Annual Meeting - 6/1/2019
Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

ECHELON-1 Update: A+AVD Bests ABVD in Hodgkin LymphomaFebruary 1st, 2020
Toxicity, Second Cancers Cause Researchers to Question Radiation’s Role in Hodgkin LymphomaApril 25th, 2016